CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment modalities. In B-cell non-Hodkgina lymphoma (NHL), CD22 expression ranges from 91% to 99% in the aggressive and indolent populations, respectively. CD22 expression occurs in more than 90% of patients with B-lineage acute lymphoblastic leukemia (ALL). CD22 is not expressed on non-B lineage cells or hematopoietic stem cells. In addition, CD22 is rapidly internalized after binding of the anti-CD22 antibody and is not shed in the extracellular environment, features that make it an attractive antigen for targeted delivery of payloads by immunotherapeutics such as antibodies or engineered T-cells.

Monotherapy of NHL and ALL with naked anti-CD22 antibodies only achieved modest efficacy results indicating the need for more effective payloads, but at the same time also providing development opportunities for new treatment modalities such as

• Combination therapies;
• Radioimmunotherapy (RIT);
• Immunotoxins (IT);
• Antibody-Dug Conjugates (ADC); and
• Chimeric Antigen Receptor (CAR) T-Cells.

This report describes the profiles of 16 different specific and bispecifi anti-CD22 immunotherapeutics based on different treatment modalities. The most advanced molecules has been submitted for regulatory approval. Furthermore, the profiles of nine companies active in the development of anti-CD22 immunotherapeutics are presented. This report describes and analyzes the

• Target Background & Scientific Rationale
• Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
• Competitive Landscape
• Profiles of Anti-CD22 Immunotherapeutics
• Profiles of Companies with CD22-Targeted Immunotherapeutics.